SCHEMBL4519352

SCHEMBL4519352

CS(=O)(=O)c1ccc(-c2ccc3[nH]c(COc4ccc(C(F)(F)F)cc4)nc3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.46
MAOB P27338 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
PKM P14618 1/20 0.42
MAPK1 P28482 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
PTGDR2 Q9Y5Y4 1/20 0.40
PTGS1 P23219 1/20 0.40
ADAMTS4 O75173 1/20 0.40
MMP13 P45452 1/20 0.40
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40
CACNA1B Q00975 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4533241 0.91 NR1H2 (0.44) PTGS2MAOBSMN1; SMN2MEN1ALDH1A1
SCHEMBL4526432 0.90 KIF11 (0.49) PTGS2MAOBSMN1; SMN2MEN1ALDH1A1
SCHEMBL4524138 0.89 MAOB (0.41) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4526082 0.89 ADAMTS4 (0.44) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4526676 0.87 KIF11 (0.52) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4531947 0.86 NPC1 (0.57) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL13628971 0.86 SMN1; SMN2 (0.57) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4529910 0.85 RAB9A (0.53) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4526333 0.85 MAOB (0.47) MAOBSMN1; SMN2MEN1ALDH1A1LMNA
SCHEMBL4517636 0.84 TRPV1 (0.51) MAOBSMN1; SMN2MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612211-B2 Benzimidazole TRPV1 inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-03 US claimed
US-20080146637-A1 BENZIMIDAZOLE TRPV1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-19 US claimed
EP-2124563-B1 BENZIMIDAZOLE TRPV1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2015-07-29 EP disclosed
US-7612211-B2 Benzimidazole TRPV1 inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2009-11-03 US disclosed
US-20080146637-A1 BENZIMIDAZOLE TRPV1 INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146637-A1 BENZIMIDAZOLE TRPV1 INHIBITORS TRPV1, TRPV2, TRPA1 PTGS2 80/4885MAOB 1031/4885SMN1; SMN2 4288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.